36 min listen
CAR T-Cells and Safety Signals
ratings:
Length:
25 minutes
Released:
Apr 24, 2024
Format:
Podcast episode
Description
This episode examines CAR T-cell therapy’s early successes, broader promise, and emerging risks, as the FDA considers reports of occasional secondary cancers.
A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp2400701.
A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp2400701.
Released:
Apr 24, 2024
Format:
Podcast episode
Titles in the series (34)
Covid Vaccines — Playing the Long Game: In this first episode of “Intention to Treat,” NEJM editor-in-chief Eric Rubin and his colleague at the FDA Vaccine Advisory Committee, Paul Offit, consider the achievements, limitations, and expectations of Covid vaccines. A transcript of this epi... by Intention to Treat